Upstream Bio Inc (UPB)

$6.36 +0.01 (0.16%)
Market Cap 343.93M
Revenue (ttm) 2.85M
Net Income (ttm) -143.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,032.98%
Debt to Equity Ratio 0.00
Volume 469,800
Avg Vol 605,104
Day's Range N/A - N/A
Shares Out 54.42M
Stochastic %K 58%
Beta 1.10
Analysts Strong Sell
Price Target $38.43

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
Gunnar1
Gunnar1 Jun. 25 at 1:55 PM
$UPB
0 · Reply
Gunnar1
Gunnar1 Jun. 25 at 1:50 PM
$UPB Piper Sandler today with "BUY2 rating and a price target of 75$ (!) 💪
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 14 at 11:56 PM
$UPB certainly "smells" like good news
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 14 at 10:08 PM
$UPB Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 "Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score"
0 · Reply
Rounderssss4
Rounderssss4 Jun. 14 at 3:18 PM
$UPB Placebo-adjusted nasal polyp score reduction of -1.95 at Week 24, nearly double the 1.0-point meaningful threshold
0 · Reply
Rounderssss4
Rounderssss4 Jun. 14 at 2:59 PM
$UPB Upstream Bio says Phase 2 VIBRANT trial shows verekitug improves nasal polyp score in about 80% of CRSwNP patients https://www.webullapp.com/news-detail/15056145028318208?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=QuotesFragment&tickerId=951001040&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=33&isLite=false&wbFontSetting=medium&wbFontUnit=29&wbFontSize=32&isSubsNews=false
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 12 at 11:57 PM
$UPB took some before the close
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 12 at 5:06 PM
$UPB bt the downgrade and upcoming presentation it appears as if no one wants to hold this name over the weekend appears so oversold but could just as easily be even more oversold in the 5s tempting but not sure i want to re-enter just yet
1 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 1:46 PM
$UPB interesting a downgrade before presentation this weekend, I'm guessing good news is coming
1 · Reply
Xrx12
Xrx12 Jun. 12 at 1:44 PM
$UPB I actually don't think this stock ever reaches double digits again
1 · Reply
Latest News on UPB
Upstream Bio management to meet with Piper Sandler

2026-06-17T20:20:10.000Z - 8 days ago

Upstream Bio management to meet with Piper Sandler

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

2026-06-14T20:55:54.000Z - 11 days ago

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Jun 14, 2026, 10:00 AM EDT - 11 days ago

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Jun 12, 2026, 5:07 PM EDT - 13 days ago

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

2026-06-12T08:55:22.000Z - 13 days ago

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

Upstream Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 10:40 AM EDT - 15 days ago

Upstream Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Upstream Bio Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 16 days ago

Upstream Bio Transcript: AGM 2026

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Jun 8, 2026, 7:00 AM EDT - 17 days ago

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 3, 2026, 7:00 AM EDT - 22 days ago

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Upstream Bio initiated with a Buy at H.C. Wainwright

2026-06-03T10:11:07.000Z - 22 days ago

Upstream Bio initiated with a Buy at H.C. Wainwright

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

2026-05-18T15:35:26.000Z - 5 weeks ago

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

May 18, 2026, 11:30 AM EDT - 5 weeks ago

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio price target lowered to $50 from $51 at Mizuho

2026-05-14T12:37:47.000Z - 6 weeks ago

Upstream Bio price target lowered to $50 from $51 at Mizuho

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Upstream Bio Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Upstream Bio Earnings release: Q1 2026

Upstream Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Upstream Bio Quarterly report: Q1 2026

Upstream Bio Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Upstream Bio Slides: Corporate presentation

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

2026-04-17T11:07:21.000Z - 2 months ago

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Apr 17, 2026, 7:00 AM EDT - 2 months ago

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Upstream Bio Proxy statement: Proxy filing

Upstream Bio Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Upstream Bio Proxy statement: Proxy filing

Upstream Bio Slides: Corporate presentation

Apr 6, 2026, 7:00 AM EDT - 2 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

2026-03-27T10:45:28.000Z - 3 months ago

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Upstream Bio Annual report: Q4 2025

Upstream Bio Earnings release: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Upstream Bio Earnings release: Q4 2025

Upstream Bio Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:40 PM EDT - 3 months ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 4 months ago

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

Upstream Bio announces verekitug met the primary endpoint

2026-03-01T16:35:25.000Z - 4 months ago

Upstream Bio announces verekitug met the primary endpoint

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Mar 1, 2026, 9:45 AM EST - 4 months ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 26, 2026, 7:00 AM EST - 4 months ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 7:00 AM EST - 4 months ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio Transcript: Study result

Feb 11, 2026, 8:00 AM EST - 4 months ago

Upstream Bio Transcript: Study result

Upstream Bio Press release: Study result

Feb 11, 2026, 8:00 AM EST - 4 months ago

Upstream Bio Press release: Study result

Upstream Bio Slides: Study result

Feb 11, 2026, 8:00 AM EST - 4 months ago

Upstream Bio Slides: Study result

Upstream Bio reports results from Phase 2 VALIANT clinical trial

2026-02-11T11:15:40.000Z - 4 months ago

Upstream Bio reports results from Phase 2 VALIANT clinical trial

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 11, 2026, 6:00 AM EST - 4 months ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Feb 10, 2026, 6:00 PM EST - 4 months ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio management to meet virtually with Piper Sandler

2026-01-20T19:55:30.000Z - 5 months ago

Upstream Bio management to meet virtually with Piper Sandler

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 5 months ago

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 5 months ago

Upstream Bio Slides: 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 5 months ago

Upstream Bio Slides: Corporate presentation

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 6 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio initiated with an Outperform at Mizuho

2025-12-17T21:16:04.000Z - 6 months ago

Upstream Bio initiated with an Outperform at Mizuho

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:25 AM EST - 7 months ago

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 4:30 PM EST - 7 months ago

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Upstream Bio initiated with an Outperform at LifeSci Capital

2025-12-02T12:15:17.000Z - 7 months ago

Upstream Bio initiated with an Outperform at LifeSci Capital

Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 25, 2025, 7:00 AM EST - 7 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 10:30 AM EST - 8 months ago

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 9:20 AM EST - 8 months ago

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

Upstream Bio Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Upstream Bio Slides: Corporate Presentation

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Nov 5, 2025, 7:00 AM EST - 8 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Upstream Bio Quarterly report: Q3 2025

Upstream Bio Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Upstream Bio Earnings release: Q3 2025

Upstream Bio to Participate in Upcoming November Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 8 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 30, 2025, 4:15 AM EDT - 9 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 15, 2025, 10:30 AM EDT - 10 months ago

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Transcript: Study Update

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Upstream Bio Transcript: Study Update

Upstream Bio Press release: Study Update

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Upstream Bio Press release: Study Update

Upstream Bio Slides: Study Update

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Upstream Bio Slides: Study Update

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 2, 2025, 6:00 AM EDT - 10 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 10 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Upstream Bio Earnings release: Q2 2025

Upstream Bio Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Upstream Bio Quarterly report: Q2 2025

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 15, 2025, 7:45 AM EDT - 1 year ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Quarterly report: Q1 2025

Upstream Bio Earnings release: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Earnings release: Q1 2025

Upstream Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Proxy statement: Proxy Filing

Upstream Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Upstream Bio Proxy statement: Proxy Filing

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio Earnings release: Q4 2024

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Earnings release: Q4 2024

Upstream Bio Annual report: Q4 2024

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Annual report: Q4 2024

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 5:15 PM EST - 1 year ago

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:00 PM EST - 1 year ago

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Upstream Bio Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Upstream Bio Quarterly report: Q3 2024

Upstream Bio Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Upstream Bio Earnings release: Q3 2024

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Gunnar1
Gunnar1 Jun. 25 at 1:55 PM
$UPB
0 · Reply
Gunnar1
Gunnar1 Jun. 25 at 1:50 PM
$UPB Piper Sandler today with "BUY2 rating and a price target of 75$ (!) 💪
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 14 at 11:56 PM
$UPB certainly "smells" like good news
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 14 at 10:08 PM
$UPB Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 "Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score"
0 · Reply
Rounderssss4
Rounderssss4 Jun. 14 at 3:18 PM
$UPB Placebo-adjusted nasal polyp score reduction of -1.95 at Week 24, nearly double the 1.0-point meaningful threshold
0 · Reply
Rounderssss4
Rounderssss4 Jun. 14 at 2:59 PM
$UPB Upstream Bio says Phase 2 VIBRANT trial shows verekitug improves nasal polyp score in about 80% of CRSwNP patients https://www.webullapp.com/news-detail/15056145028318208?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=QuotesFragment&tickerId=951001040&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=33&isLite=false&wbFontSetting=medium&wbFontUnit=29&wbFontSize=32&isSubsNews=false
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 12 at 11:57 PM
$UPB took some before the close
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 12 at 5:06 PM
$UPB bt the downgrade and upcoming presentation it appears as if no one wants to hold this name over the weekend appears so oversold but could just as easily be even more oversold in the 5s tempting but not sure i want to re-enter just yet
1 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 1:46 PM
$UPB interesting a downgrade before presentation this weekend, I'm guessing good news is coming
1 · Reply
Xrx12
Xrx12 Jun. 12 at 1:44 PM
$UPB I actually don't think this stock ever reaches double digits again
1 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 9:40 AM
$UPB New data to be presented this weekend. Looking for a rebound in stock price
0 · Reply
Xrx12
Xrx12 Jun. 8 at 6:05 PM
$UPB going to penny stock territory soon
0 · Reply
Xrx12
Xrx12 Jun. 5 at 8:05 PM
$UPB good chance this hits it's all time low. Stock may have performed better if they failed Ph2b
0 · Reply
Xrx12
Xrx12 Jun. 5 at 3:26 PM
$UPB RIP
0 · Reply
notreload_ai
notreload_ai Jun. 3 at 2:51 PM
$DOCN $UPB $WPP -- THE WSJ
0 · Reply
Xrx12
Xrx12 Jun. 2 at 8:02 PM
$UPB buy tomorrow on another 15% haircut.
0 · Reply
Xrx12
Xrx12 Jun. 2 at 7:22 PM
$UPB no buying even at these prices. Looks like it's going far down
0 · Reply
Xrx12
Xrx12 Jun. 2 at 2:39 PM
$UPB going to 6s even
0 · Reply
Gunnar1
Gunnar1 May. 29 at 3:33 PM
$UPB Stepping back in here, starter for me.
0 · Reply
Xrx12
Xrx12 May. 28 at 8:46 PM
$UPB do we see 7s tomorrow?
0 · Reply
Xrx12
Xrx12 May. 19 at 7:57 PM
$UPB it's crazy how they can drag a phase 3 ready asset that is highly derisked to cash levels, but will be a buyer off this manipulation soon
0 · Reply
Trainguy1
Trainguy1 May. 15 at 3:26 PM
$UPB Upstream Bio will present new data on two posters from their Phase 2 VIBRANT trial of verekitug at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida, on Monday, May 18, 2026, from 11:30 AM to 1:15 PM ET. The posters will be presented during the "B32 – Rise of the Biologics: A New Hope for Breathing Easier" session.
0 · Reply